The long-term survival of this patient, now at 80 months, could be due in part to a therapeutic metabolic synergy between KMT and the <i>IDH1</i> mutation that simultaneously target the glycolysis and glutaminolysis pathways that are essential for GBM growth. This evidence concerns the gene IDH1 and glioblastoma.